CAS No. |
150829-29-1 |
|---|---|
中文名称 |
环状吡喃嘧啶单磷酸(Fosdenopterin,cPMP) |
英文名称 |
Fosdenopterin |
别名 |
(4aR,5aR,11aR,12aS)-8-amino-2,12,12-trihydroxy-4a,5a,6,9,11,11a,12,12a-octahydro-[1,3,2]dioxaphosphinino[4',5':5,6]pyrano[3,2-g]pteridin-10(4H)-one2-oxide;EOS-60323;Fosdenopterin;1,3,2-Dioxaphosphorino[4',5':5,6]pyrano[3,2-g]pteridin-10(4H)-one, 8-amino-4a,5a,6,9,11,11a,12,12a-octahydro-2,12,12-trihydroxy-, 2-oxide, (4aR,5aR,11aR,12aS)-;Lenacapavir Impurity 14 |
标准英文名 |
(4aR,5aR,11aR,12aS)-8-amino-2,12,12-trihydroxy-4a,5a,6,9,11,11a,12,12a-octahydro-[1,3,2]dioxaphosphinino[4',5':5,6]pyrano[3,2-g]pteridin-10(4H)-one 2-oxide |
分子式 |
C10H14N5O8P |
分子量 |
363.22 |
精确分子量 |
363.06 |
SMILES |
OC1(O)[C@]2([C@@](O[C@]3([C@@]1(OP(=O)(O)OC3)[H])[H])(NC4=C(N2)C(=O)N=C(N)N4)[H])[H] |
标准SMILES |
NC1NC2N[C@@H]3O[C@@H]4COP(O)(=O)O[C@@H]4C(O)(O)[C@@H]3NC=2C(=O)N=1 |
用途 |
Fosdenopterin is a drug developed by Alexion Pharmaceuticals that was approved by the US FDA in 2021 to reduce the risk of death in patients with molybdenum cofactor deficiency type A (MoCD Type A). MoCD is a rare genetic disorder that leads to neurodegeneration and early mortality. Clinical trials have shown that replacement therapy with synthetic cPMP/fosdenopterin in patients with MoCD Type A significantly reduces mortality risk, increases survival time, and lowers urinary sulfocysteine (SSC) levels, which, when elevated, are known to cause irreversible neurological damage. |
InChIKey |
CZAKJJUNKNPTTO-AJFJRRQVSA-N |
|
|
评论 |
|---|